A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
← catalyst calendarNCT06680258 · readout ≤ 865 d
Sponsored by Tempest Therapeutics (industry) · TPST — their whole pipeline →. With Hoffmann-La Roche.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
740estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2025 | estimated | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma (HCC)
Interventions
- Drug: TPST-1120
- Biological: Atezolizumab
- Biological: Bevacizumab
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured The time from randomization to death from any cause up to 60 months.
Permalink · TPST's whole pipeline · Catalyst calendar · Every registered study · What changed